Er farmakogenetisk CYP2D6-testing nyttig

Tidsskrift for den Norske Laegeforening

Volumn 130, Issue 22, 2010, Pages 2224-2228

  Vetti, Hildegunn Høberg ^a   Molven, Anders ^a,b   Eliassen, Aud K H ^a   Steen, Vidar M ^a  

^a Haukeland universitetssykehus ^*  (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ALLELE; ARTICLE; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; MENTAL DISEASE; METABOLISM; NORWAY; PHARMACOGENETICS; RETROSPECTIVE STUDY;

ALLELES; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; NORWAY; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 78650603918     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.1445     Document Type: Article

References (24)

1. Spigset O. Skreddersydd legemiddelbehandling? hvor nær målet er vi? Tidsskr Nor Lægeforen 2006; 126: 2390-6.
2. de Leon J, Arranz MJ, Ruaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008; 28: 599-617.
3. Loovers HM, van der Weide J. Implementation of CYP2D6 genotyping in psychiatry. Expert Opin Drug Metab Toxicol 2009; 5: 1065-77.
4. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9: 576-86.
5. Ingelman-Sundberg M, Sim SC, Gomez A et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
6. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-73.
7. Rudberg I, Solberg DK, Refsum H. CYP-genotyping ved psykofarmakologisk behandling. Tidsskr Nor Lægeforen 2005; 125: 2953-5.
8. Andreassen OA, Steen VM. Farmakogenetikk og skreddersydd behandling ved schizofreni. Tidsskr Nor Lægeforen 2006; 126: 2400-2.
9. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-43.
10. Sistonen J, Sajantila A, Lao O et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93-101.
11. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-44.
12. Chen S, Chou WH, Blouin RA et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522-34.
13. Thakur M, Grossman I, McCrory DC et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007; 9: 826-35.
14. Rodríguez-Antona C, Gurwitz D, de Leon J et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 2009; 10: 685-99.
15. The Pharmacogenomics Knowledge Base. The Clinical Pharmacogenetics Implementation Consortium. www.pharmgkb.org (20.4.2010).
16. Norsk legemiddelhåndbok for helsepersonell. Oslo: Fagbokforlaget, 2007: 1318-20.
17. Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008; 19: 56-61.
18. Steen VM, Andreassen OA, Daly AK et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-23.
19. Sachse C, Brockmöller J, Bauer S et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
20. Løvlie R, Daly AK, Molven A et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30-4.
21. Tomalik-Scharte D, Lazar A, Fuhr U et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4-15.
22. Dezentjé VO, Guchelaar HJ, Nortier JW et al. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009; 15: 15-21.
23. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009; 59: 81-9.
24. Gjelsvik R, Kaarbøe O, Haukland HH et al. Hvordan kan bruk av laboratorietjenester styres? Tidsskr Nor Legeforen 2008; 128: 840.